| Identification | Back Directory | [Name]
LY3214996 | [CAS]
1951483-29-6 | [Synonyms]
CS-2495
LY3214996
6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one
4H-Thieno[2,3-c]pyrrol-4-one, 5,6-dihydro-6,6-dimethyl-2-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]-5-[2-(4-morpholinyl)ethyl]- | [Molecular Formula]
C22H27N7O2S | [MDL Number]
MFCD31544324 | [MOL File]
1951483-29-6.mol | [Molecular Weight]
453.56 |
| Chemical Properties | Back Directory | [Boiling point ]
711.5±70.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:23.5(Max Conc. mg/mL);51.81(Max Conc. mM)
Ethanol:16.0(Max Conc. mg/mL);35.28(Max Conc. mM) | [form ]
A crystalline solid | [pka]
6.58±0.10(Predicted) |
| Hazard Information | Back Directory | [Description]
LY3214996 is an inhibitor of ERK1 and ERK2 (IC50 = 5 nM for both). It inhibits cell proliferation of tumor cells in vitro, including those expressing B-RAF, N-Ras, or K-Ras mutations. LY3214996 inhibits tumor growth in B-RAF or N-Ras mutant melanoma, B-RAF or K-Ras mutant colorectal, lung, and pancreatic cancer mouse xenograft models, as well as patient-derived xenograft (PDX) mouse models. |
|
|